Latest News

November 3, 2014

CALIBRATE Trial for Lupus Nephritis Opens

Last Friday the Immune Tolerance Network (ITN) opened a new combination therapy study in lupus nephritis, CALIBRATE, at University of California, San Francisco (UCSF). The CALIBRATE Study will be led by Drs.

October 29, 2014

Abatacept for Lupus Nephritis (the ACCESS Study)

The results of the ACCESS study, “Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis” sponsored by the Immune Tolerance Network (ITN) and led by Drs.

October 22, 2014

ITN Will Receive National Academies' Award For TrialShare On October 23rd

The Immune Tolerance Network (ITN) will receive the National Academies' Board on Research Data and Information Challenge Award for TrialShare on October 23rd, 2014. Adam Asare will accept the award on behalf of the ITN during the Symposium on the Interagency Strategic Plan for Big Data: Focus on R&D at the National Academy of Sciences Keck Building, Room 100. More information can be found here.

October 9, 2014

ITN Launches the CATNIP Cat Allergy Immunotherapy Study

On Wednesday, October 8th the ITN opened the CATNIP study, “Anti-TSLP plus antigen-specific immunotherapy for induction of tolerance in individuals with cat allergy,” at the first site, the University of Wisconsin.  CATNIP will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP antibody being co-developed by Amgen and Medimmune) can lead to lasting tolerance to cat allergen.This study will implement the concept referred to as “allergen-plus,” which ai

July 28, 2014

New White Paper - Tolerance: One Transplant for Life

A White Paper published yesterday in Transplantation (co-authored by ITN Deputy Director Larry Turka, MD) outlines recommendations from an international workshop convened by The Transplantation Society (TTS) to determine the necessary steps to make tolerance protocols a standard of care for transplant over the next decade.  To date three academic centers have employed successful tolerance-inducing protocols in kidney transplant recipients (Stanford University, Northwestern University, and Massachusetts General Hospital – the MGH studies we

July 16, 2014

Immune Tolerance Network’s (ITN) TrialShare Wins National Academies Board on Research Data and Information Challenge

The Immune Tolerance Network’s (ITN) TrialShare Clinical Trials Research Portal (www.ITNTrialShare.org) has won the National Academy of Sciences Data and Information Challenge. The theme of this year’s competition, launched and judged by the academy’s Board on Research Data and Information (BDRI), was “Using Data for the Public Good.”The ITN’s entry, entitled “ITN TrialShare: Enabling True Clinical Trial Transparency” describes the unique data sharing portal developed by the NIH-sponsored clinical research consortium.

June 27, 2014

Request for Proposals: Clinical Trials of Immune Tolerance in Transplantation Using Deceased-Donor Organs

The Immune Tolerance Network (ITN) is currently seeking proposals for clinical tolerance trials in transplantation using solid organs or islets from deceased donors. Proposals should meet the following criteria: There is strong support with preclinical data and/or evidence from clinical pilot studies; if preclinical studies alone are used to support the proposal, these studies should include brain dead donors or discuss why such studies are not needed with the proposed protocol. The donor and recipient are HLA mismatched.

June 25, 2014

"Mechanisms of Tolerance" Symposium at Annual FOCIS Meeting

The ITN is hosting a Member Society Symposium entitled “Mechanisms of Tolerance” on June 25th, 2014 (12:45-pm-4:45pm CT) during the annual Federation of Clinical Immunology Societies (FOCIS) meeting in Chicago,  IL.

May 6, 2014

Restoring the Balance: Immunotherapeutic Combinations for Autoimmune Disease

An article published last week in Disease Models and Mechanisms by Dawn Smilek, MD, PhD, Mario Ehlers, MD, PhD, and Jerry Nepom, MD, PhD, provides a review of mechanisms involved in the disruption of tolerance to self-antigens in autoimmune disease, highlighting where those mechanisms can be targeted as a means of restoring tolerance and durably reversing autoimmune pathology.

February 21, 2014

ITN Launches the PAUSE Study in Psoriasis

Today the ITN launched the PAUSE study (ITN059AI, “Efficacy of Ustekinumab followed by Abatacept for the Treatment of Psoriasis Vulgaris”), which will test the combination of two biologics, ustekinumab (Janssen Biotech, Inc.) and abatacept (Bristol-Myers Squibb), in psoriasis patients. This study is being led by James Krueger, MD, PhD (The Rockefeller University).